Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

STACKD0E Aug. 24 at 9:02 PM

$DRMA 🙃✨️

0 · Reply

Merlintrader Aug. 24 at 7:43 PM

$DRMA Dermata opened preorders for Tome Foundational Treatment on August 21, four days before the planned commercial launch of August 25. Shipping is expected to start on the launch date. The release restates the 178 dollar price, about 45 dollars a treatment, and adds one thing the August 5 announcement did not carry: subscribers get 10 per cent off, which puts a subscribed set at 160.20 dollars, or 40.05 a treatment. No preorder units, no revenue and no Form 8-K travelled with it. The first verifiable measure of demand is the third-quarter filing. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/dermata-therapeutics-drma-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=drma-preordini

0 · Reply

brallt Aug. 24 at 11:30 AM

$DRMA 2 trading days left.

0 · Reply

_El_Capitan Aug. 21 at 12:36 PM

$DRMA Announces Preorders Now Open LOL NA

0 · Reply

STACKD0E Aug. 21 at 12:34 PM

$DRMA 👀

0 · Reply

Stock_Catcher Aug. 21 at 12:30 PM

$DRMA Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

0 · Reply

Investor6 Aug. 20 at 7:40 PM

ARBB is a Singapore based stock with business in Singapore and Malaysia. Its executives are not Chinese. $MWG is also Singaporean. ARBB had high growth in the first semester of the fiscal year, while it trades at a ridiculous low Price/Sales. $DRMA $EHGO $CLIS

0 · Reply

MoneyMacG Aug. 20 at 6:35 PM

$PARA.X $MWG $DRMA $EHGO $CLIK solid

0 · Reply

brallt Aug. 19 at 2:21 PM

$DRMA Not much time left to slowly accumulate for the fundemental shift that the product launch at the end of the month will bring to the balance sheet. They are already taking pre-orders for sales/shipping out product.

0 · Reply

ShangVXO Aug. 19 at 11:42 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $YYGH and $DRMA are too underrated

0 · Reply

Dermata Therapeutics announces Tome Foundational Treatment open to preorders

Aug 21, 2026, 8:30 AM EDT - 3 days ago

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

2026-08-17T12:45:56.000Z - 7 days ago

Dermata Therapeutics prices 2.29M shares at $1.46 in private placement

Aug 17, 2026, 8:30 AM EDT - 7 days ago

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aug 11, 2026, 4:05 PM EDT - 13 days ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Aug 11, 2026, 4:00 PM EDT - 13 days ago

Dermata Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 13 days ago

Dermata Therapeutics Quarterly report: Q2 2026

2026-08-05T14:10:33.000Z - 19 days ago

Dermata to commercially launch Tome Foundational Treatment on August 25

Aug 5, 2026, 8:30 AM EDT - 19 days ago

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

May 22, 2026, 8:00 AM EDT - 3 months ago

Dermata Therapeutics Registration statement: Registration filing

May 13, 2026, 4:05 PM EDT - 3 months ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Dermata Therapeutics Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Dermata Therapeutics Earnings release: Q1 2026

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Dermata Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Dermata Therapeutics Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Dermata Therapeutics Proxy statement: Proxy filing

2026-04-02T12:39:24.000Z - 5 months ago

Dermata receives notice of acceptance of Australian patent application

Apr 2, 2026, 8:30 AM EDT - 5 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

2026-04-01T12:35:12.000Z - 5 months ago

Dermata Therapeutics price target lowered to $4 from $10 at Maxim

Mar 26, 2026, 5:15 PM EDT - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Dermata Therapeutics Annual report: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Dermata Therapeutics Earnings release: Q4 2025

2026-03-10T12:50:38.000Z - 5 months ago

Dermata Therapeutics appoints Kyra Peckaitis as VP, marketing

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

2026-03-05T14:07:31.000Z - 6 months ago

Dermata Therapeutics announces release of Tome Skincare

Mar 5, 2026, 9:00 AM EST - 6 months ago

Dermata Opens a New Chapter with the Release of Tome Skincare

2026-01-22T22:05:25.000Z - 7 months ago

Dermata Therapeutics files to sell 1.48M shares of common stock for holders

Jan 22, 2026, 7:00 AM EST - 7 months ago

Dermata Therapeutics Registration statement: Registration filing

2026-01-20T13:55:47.000Z - 7 months ago

Dermata Therapeutics receives notice of grant of patent for acne treatment

Jan 20, 2026, 8:05 AM EST - 7 months ago

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025, 4:05 PM EST - 8 months ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2025-12-24T13:15:17.000Z - 8 months ago

Dermata Therapeutics prices 2.02M shares at $2.04 in private placement

Dec 24, 2025, 8:00 AM EST - 8 months ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2025-12-04T13:16:01.000Z - 9 months ago

Dermata Therapeutics to reveal brand name for OTC skincare business

Dec 4, 2025, 8:00 AM EST - 9 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

2025-11-24T16:35:08.000Z - 9 months ago

Dermata Therapeutics files $100M mixed securities shelf

Nov 24, 2025, 7:00 AM EST - 9 months ago

Dermata Therapeutics Registration statement: Registration filing

Nov 14, 2025, 4:05 PM EST - 10 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 7:00 AM EST - 10 months ago

Dermata Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

Dermata Therapeutics Earnings release: Q3 2025

2025-10-02T12:15:09.000Z - 11 months ago

Dermata says Australian Patent Office accepts Spongilla tech application

Oct 2, 2025, 8:00 AM EDT - 11 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 1 year ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

2025-09-10T12:20:14.000Z - 1 year ago

Dermata Therapeutics announces strategic pivot to OTC skin care treatments

2025-09-10T12:20:09.000Z - 1 year ago

Dermata Therapeutics withdraws IND application for XYNGARI

Sep 10, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

2025-08-21T13:00:32.000Z - 1 year ago

Dermata Therapeutics price target lowered to $10 from $30 at Maxim

Aug 13, 2025, 5:00 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Earnings release: Q2 2025

2025-07-31T23:50:23.000Z - 1 year ago

Dermata Therapeutics Inc trading halted, news pending

2025-07-08T12:50:59.000Z - 1 year ago

Dermata Therapeutics receives notice of grant of Australian patent

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Proxy statement: Proxy filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Proxy statement: Proxy filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Proxy statement: Proxy filing

2025-05-21T12:10:24.000Z - 1 year ago

Dermata Therapeutics price target lowered to $3 from $6 at Maxim

2025-05-14T13:25:20.000Z - 1 year ago

Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year

May 14, 2025, 9:00 AM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Earnings release: Q1 2025

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Registration statement: Registration filing

Mar 27, 2025, 8:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 9:57 AM EDT - 1 year ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Annual report: Q4 2024

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 8:03 AM EST - 1 year ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 30, 2025, 7:00 AM EST - 1 year ago

Dermata Therapeutics Registration statement: Registration filing

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 1 year ago

Dermata Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Dermata Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 2 years ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 19, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Registration statement: Registration filing

Sep 17, 2024, 5:15 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 2 years ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Earnings release: Q2 2024

Jul 17, 2024, 9:00 AM EDT - 2 years ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Registration statement: Registration filing

May 17, 2024, 8:30 AM EDT - 2 years ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Quarterly report: Q1 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Earnings release: Q1 2024

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Earnings release: Q4 2023

Mar 4, 2024, 7:00 AM EST - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

STACKD0E Aug. 24 at 9:02 PM

$DRMA 🙃✨️

0 · Reply

Merlintrader Aug. 24 at 7:43 PM

0 · Reply

brallt Aug. 24 at 11:30 AM

$DRMA 2 trading days left.

0 · Reply

_El_Capitan Aug. 21 at 12:36 PM

$DRMA Announces Preorders Now Open LOL NA

0 · Reply

STACKD0E Aug. 21 at 12:34 PM

$DRMA 👀

0 · Reply

Stock_Catcher Aug. 21 at 12:30 PM

$DRMA Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

0 · Reply

Investor6 Aug. 20 at 7:40 PM

0 · Reply

MoneyMacG Aug. 20 at 6:35 PM

$PARA.X $MWG $DRMA $EHGO $CLIK solid

0 · Reply

brallt Aug. 19 at 2:21 PM

0 · Reply

ShangVXO Aug. 19 at 11:42 AM

0 · Reply

sv13021 Aug. 17 at 11:35 PM

$DRMA whats with the drop?

0 · Reply

Louiedog96 Aug. 17 at 7:21 PM

$DRMA it’s go time

0 · Reply

brallt Aug. 17 at 12:55 PM

$DRMA Insiders and CEO are putting their money where their mouth is. Instead of an retail atm offering They bought at 1.47. If the CEO and insuders are front running the product launch as a Long, they have less of a interest to dilute the product launch and pump it as much as they can for their own personal gain.

0 · Reply

STACKD0E Aug. 17 at 12:53 PM

$AIDX $DRMA $CSAI $NCTY 👀

0 · Reply

Trade_Weaver Aug. 17 at 12:31 PM

$DRMA private placement this morning!

0 · Reply

sv13021 Aug. 17 at 4:28 AM

$DRMA Where we heading this week?

1 · Reply

HolEKa1010 Aug. 17 at 1:27 AM

$DRMA

0 · Reply

Rick2058 Aug. 14 at 7:06 PM

$DRMA Added some.

0 · Reply

Gotalife Aug. 14 at 6:44 PM

$DRMA Gerry Proehl is a Founder, President, CEO and Director of Dermata Therapeutics, Inc. Formerly he was President and CEO of Santarus, Inc., where he led the sale of Santarus to Salix Pharmaceuticals for $2.6 billion. Prior to Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc. In case you want to do more DD over the weekend.

0 · Reply

Atore Aug. 14 at 5:08 PM

$FRGT a clear breakout of 1.92 you will agressive run $DRMA $INHD

0 · Reply

Atore Aug. 14 at 3:58 PM

I gave you guys $DRMA at 1.35 and I am giving you the reverse inbound now $FRGT get in Thank me later

0 · Reply

TA_Kongen Aug. 14 at 1:39 PM

$DRMA Setting up for a potential 1.80s clear.

0 · Reply

Market Cap	5.71M
Revenue (ttm)	0.00
Net Income (ttm)	-7.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	210,518
Avg Vol	912,498
Day's Range	N/A - N/A
Shares Out	4.02M
Stochastic %K	63%
Beta	0.66
Analysts	Strong Sell
Price Target	$4.00